AX9 Stock Overview
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Akebia Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.20 |
| 52 Week High | US$2.85 |
| 52 Week Low | US$0.71 |
| Beta | 0.84 |
| 1 Month Change | -32.47% |
| 3 Month Change | -12.39% |
| 1 Year Change | 69.77% |
| 3 Year Change | -57.07% |
| 5 Year Change | -77.36% |
| Change since IPO | -91.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| AX9 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -5.9% | -0.2% | 0.5% |
| 1Y | 69.8% | -22.8% | 1.3% |
Price Volatility
| AX9 volatility | |
|---|---|
| AX9 Average Weekly Movement | 14.6% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: AX9's share price has been volatile over the past 3 months.
Volatility Over Time: AX9's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 167 | John Butler | www.akebia.com |
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis.
Akebia Therapeutics, Inc. Fundamentals Summary
| AX9 fundamental statistics | |
|---|---|
| Market cap | €267.39m |
| Earnings (TTM) | -€48.40m |
| Revenue (TTM) | €181.43m |
1.4x
P/S Ratio-5.4x
P/E RatioIs AX9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AX9 income statement (TTM) | |
|---|---|
| Revenue | US$194.62m |
| Cost of Revenue | US$39.76m |
| Gross Profit | US$154.86m |
| Other Expenses | US$206.78m |
| Earnings | -US$51.92m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 79.57% |
| Net Profit Margin | -26.68% |
| Debt/Equity Ratio | -296.7% |
How did AX9 perform over the long term?
See historical performance and comparison